Skip Nav Destination
Issues
1 April 2013
-
Cover Image
Cover Image
Suppression of aberrant DNA methylation is a novel approach to cancer prevention, but so far the efficacy of the strategy has not been evaluated in cancers associated with chronic inflammation. Gastric cancers (GCs) induced by Helicobacter pylori (HP) infection are known to involve aberrant DNA methylation and are associated with severe chronic inflammation in their early stages. Using the DNA demethylating agent 5-aza-2′-deoxycytidine (5-aza-dC), suppression of aberrant DNA methylation to prevent HP-induced GCs was investigated using a Mongolian gerbil model. The incidence of GCs induced by HP infection and N-methyl-N-nitrosourea (MNU) treatment as well as global DNA methylation levels were significantly decreased in gerbils treated with 5-aza-dC (50–55 weeks) compared to vehicle. Extra-gastric tissues were tested to assess adverse effects of 5-aza-dC, which included testicular atrophy. The cover micrograph shows a magnified view of tissue sections of nonatrophied testes in vehicle-treated gerbils. These results show that 5-aza-dC treatment can prevent HP-induced GCs and suggest that removal of induced DNA methylation and/or suppression of DNA methylation induction can become a target for prevention of chronic inflammationassociated cancers. See article by Niwa and colleagues (beginning on page 263) for more information. - PDF Icon PDF LinkTable of Contents
ISSN 1940-6207
EISSN 1940-6215
Issue Sections
Commentary
Perspective
Research Articles
Effects of Ginger Supplementation on Cell-Cycle Biomarkers in the Normal-Appearing Colonic Mucosa of Patients at Increased Risk for Colorectal Cancer: Results from a Pilot, Randomized, and Controlled Trial
Jessica Citronberg; Roberd Bostick; Thomas Ahearn; D. Kim Turgeon; Mack T. Ruffin; Zora Djuric; Ananda Sen; Dean E. Brenner; Suzanna M. Zick
Inhibition of 15-Hydroxyprostaglandin Dehydrogenase by Helicobacter pylori in Human Gastric Carcinogenesis
Yeon-Mi Ryu; Seung-Jae Myung; Young Soo Park; Dong-Hoon Yang; Ho June Song; Jin-Yong Jeong; Sun Mi Lee; Miyeoun Song; Do Hoon Kim; Hyo-Jeong Lee; Soo-Kyung Park; Stephen P. Fink; Sandy D. Markowitz; Kee Wook Jung; Kyung-Jo Kim; Byong Duk Ye; Jeong-Sik Byeon; Hwoon-Yong Jung; Suk-Kyun Yang; Jin-Ho Kim
Research Article
Letter to the Editor
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.